BradyXplore: Bradykinesia Feature Extraction System

BradyXplore：运动迟缓特征提取系统

• 批准号: 8394227
• 负责人: Dustin A. Heldman
• 金额: $ 77.52万
• 依托单位: GREAT LAKES NEUROTECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8394227
• 关键词: Accounting; Affect; Algorithms; Bradykinesia; Businesses; Calibration; Charge; Clinic; Clinical; Clinical Research; Clinical Trials; Complex; Computer software; Computers; Data; Deep Brain Stimulation; Development; Device or Instrument Development; Diagnostic; Disease; Ensure; Evaluation; Fatigue; Fingers; Hand; Health Insurance Portability and Accountability Act; Home environment; Implant; Instruction; Intervention; Link; Measurement; Measures; Medical Device; Modeling; Monitor; Motion; Motor; Movement; Movement Disorders; Online Systems; Outcome Assessment; Output; Parkinson Disease; Patients; Pattern; Peer Review; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Pronation; Publications; Quality of life; Radio; Reporting; Research; Severities; Specialist; Speed; Supination; Symptoms; System; Tablets; Technology; Testing; Therapeutic Intervention; Thumb structure; Time; Treatment Efficacy; Tremor; United States; Universities; Weight; Wireless Technology; design; ergonomics; experience; functional disability; improved; innovation; kinematics; neuromechanism; neurotechnology; novel; novel therapeutic intervention; response; sensor; tool; web interface

DESCRIPTION (provided by applicant): The objective is to design, implement, and clinically assess a portable, user-worn, bradykinesia feature extraction system, BradyXplore", for integration with Great Lake Neurotechnologies' (GLN) Kinesia and Kinesia HomeView technology platforms for objective Parkinson's disease (PD) monitoring. There has been tremendous research into PD treatments including pharmaceutical interventions and deep brain stimulation (DBS). While tremor is often the most visible symptom, bradykinesia can be the most impairing. The current standard in evaluating bradykinesia is the Unified Parkinson's Disease Rating Scale, a subjective, qualitative ranking system. Scoring instructions for bradykinesia integrate multiple movement features into a single score that increases variability and limits exploration into if particular bradykinesia features are influenced by specific treatments. If different bradykinesia features were better quantified, novel therapies may be developed to target specific bradykinesia manifestations. The proposed innovations include 1) compact, user-worn motion sensors that can be used with web-based software on a home computer or tablet, 2) algorithms that use kinematic data to rate speed, amplitude, and rhythm independently, and 3) web-based applications for system delivery, patient interaction, and symptom reporting, all of which will promote clinical acceptance and a self- sustaining business model. Wireless motion sensor units containing accelerometers and gyroscopes will be worn on the finger and thumb and collect synchronized motion data. BradyXplore will independently rate speed, amplitude, and rhythm for the standard repetitive motion tasks. Sensor unit batteries will be recharged by an inductive, USB charge pad to eliminate the need for patients to fidget with small connectors. When sensor units are placed on the pad, kinematic data will be transferred to the patient's computer or tablet via a wireless link and then uploaded to our HIPAA-compliant server. In Phase I, our existing motion sensor unit was successfully upgraded to reduce size and improve sensitivity. Algorithms were developed for independently rating speed, amplitude, and rhythm. The algorithms output scores highly correlated to clinical ratings and demonstrated a differential response of speed, amplitude, and rhythm to medication. Phase II will improve ergonomics, sensitivity, data transfer, and reporting. Hardware will be upgraded to include two synchronized sensor units that recharge via an inductive pad and transfer data via a low-power radio. Software will be modified to be completely web-based so patients need not install any software. BradyXplore algorithms will be further investigated in a clinical study to demonstrate its test-retest reliability compared to clinical ratings and determine if speed, amplitude, and rhythm fluctuate differentially ON DBS. We hypothesize that BradyXplore will 1) provide a standardized platform for bradykinesia assessment that objectively quantifies speed, amplitude, and rhythm, 2) receive high clinical acceptance from both clinicians and patients, and 3) aid in development, evaluation, and optimization of therapies such as DBS and pharmaceutical interventions. PUBLIC HEALTH RELEVANCE: Parkinson's disease affects approximately 1.5 million people in the United States causing motor symptoms, of which one of the most debilitating is bradykinesia (slowed movements). Bradykinesia is currently evaluated using a subjective rating scale that gives a single score taking into account speed, amplitude, fatiguing, hesitations, arrests in movement, and how these variables change over time. The proposed BradyXplore bradykinesia feature extraction system will separately quantify specific features of bradykinesia (speed, amplitude, and rhythm) in the home, which should aid in the development of novel therapies to target a patient's specific bradykinesia manifestations.

描述（由申请人提供）：目标是设计、实施和临床评估便携式、用户佩戴的运动迟缓特征提取系统 BradyXplore，用于与 Great Lake Neurotechnologies (GLN) 的 Kinesia 和 Kinesia HomeView 技术平台集成，以进行客观的帕金森病 (PD) 监测。针对 PD 治疗进行了大量研究，包括药物干预和深部脑刺激 （星展银行）。虽然震颤通常是最明显的症状，但运动迟缓可能是最严重的损害。目前评估运动迟缓的标准是统一帕金森病评定量表，这是一种主观的定性排名系统。运动迟缓的评分指令将多个运动特征整合到一个分数中，这增加了可变性并限制了对特定运动迟缓特征是否受到特定治疗的影响的探索。如果不同 运动迟缓特征得到了更好的量化，可以开发新的疗法来针对特定的运动迟缓表现。拟议的创新包括 1) 紧凑型、用户佩戴的运动传感器，可与家用计算机或平板电脑上基于网络的软件一起使用，2) 使用运动学数据独立评估速度、幅度和节律的算法，以及 3) 用于系统交付、患者交互和症状报告的基于网络的应用程序，所有 其中将促进临床接受度和自我维持的商业模式。包含加速计和陀螺仪的无线运动传感器单元将佩戴在手指和拇指上并收集同步运动数据。 BradyXplore 将独立评估标准重复运动任务的速度、幅度和节奏。传感器单元电池将通过感应 USB 充电板充电，以消除患者烦躁的需要 带有小连接器。当传感器单元放置在垫上时，运动学数据将通过无线链路传输到患者的计算机或平板电脑，然后上传到我们符合 HIPAA 标准的服务器。在第一阶段，我们现有的运动传感器单元成功升级，以减小尺寸并提高灵敏度。开发了用于独立评估速度、幅度和节奏的算法。该算法的输出分数与以下因素高度相关： 临床评级并表现出对药物的速度、幅度和节律的不同反应。第二阶段将改善人体工程学、灵敏度、数据传输和报告。硬件将升级，包括两个同步传感器单元，它们通过感应垫充电并通过低功率无线电传输数据。软件将被修改为完全基于网络，因此患者无需安装任何软件。 BradyXplore 算法将是 在一项临床研究中进一步进行了研究，以证明其与临床评级相比的重测可靠性，并确定 DBS 上的速度、幅度和节律是否有差异波动。我们假设 BradyXplore 将 1) 为运动迟缓评估提供一个标准化平台，客观地量化速度、幅度和节律，2) 获得临床医生和患者的高度临床认可，3) 帮助开发， 评估和优化 DBS 和药物干预等疗法。 公共卫生相关性：帕金森病在美国影响大约 150 万人，导致运动症状，其中最使人衰弱的症状之一是运动迟缓（运动缓慢）。目前，运动迟缓使用主观评分量表进行评估，该评分量表考虑了速度、幅度、疲劳、犹豫、运动停止以及这些变量随时间的变化情况，给出单一分数。拟议的 BradyXplore 运动迟缓特征提取系统将单独量化家中运动迟缓的具体特征（速度、幅度和节律），这将有助于开发针对患者特定运动迟缓表现的新疗法。